UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                 _______________

                                    FORM 8-K

                                 CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

               Date of Report (Date of earliest event reported)
                    December 16, 2005 (December 15 2005)
                                _______________

                       DIALYSIS CORPORATION OF AMERICA
           (Exact name of registrant as specified in its charter)

          Florida                       0-8527                59-1757642
(State or other jurisdiction          (Commission           (IRS Employer
      of incorporation)               File Number)        Identification No.)

1302 Concourse Drive, Suite 204, Linthicum, MD                  21090
   (Address of principal executive offices)                   (Zip Code)

     Registrant's telephone number, including area code: (410) 694-0500

                                _______________

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement

     On October 24, 2005, Dialysis Corporation of America (the "Company")
entered into a Credit Agreement with Keybank National Association
("Keybank"), pursuant to which Keybank has provided the Company with a $15
million secured revolving credit facility (the "Credit Agreement") by means
of any combination of base rate loans and/or LIBOR loans.  The Credit
Agreement was reported in a Current Report on Form 8-K dated October 27,
2005.  Keybank and the Company entered into Amendment No. 1 to Credit
Agreement redefining consolidated net worth.

     The proceeds of the Credit Agreement are intended to be used for
development and acquisition of new dialysis centers, working capital needs,
and for other general corporate purposes.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
          Off-Balance Sheet Arrangement of a Registrant

     The information relating to the Company's entry into Amendment No. 1 to
Credit Agreement is set forth in Item 1.01 above, and is incorporated in this
Item 2.03 by reference.

Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         (10) Material Contracts

              (i) Amendment No. 1 to Credit Agreement between the Company and
                  Keybank National Association dated December 15 2005

                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       DIALYSIS CORPORATION OF AMERICA

                                          /s/ Stephen W. Everett
                                       By--------------------------------
                                          STEPHEN W. EVERETT
                                          President and Chief Executive
                                          Officer

Dated:  December 16, 2005